Connect with us

Health

Study Confirms Generic Drugs in India Match Brand Quality

Editorial

Published

on

A recent citizen-funded study has revealed that generic medicines in India are equivalent in quality to their more expensive branded counterparts. This significant finding has the potential to reshape healthcare affordability for millions of people across the country. The research, titled The Citizens Generic versus Brand Drugs Quality Project, tested 131 samples from various categories, demonstrating that all generic drugs met rigorous quality standards.

The findings, released on January 12, 2024, indicate a complete refutation of long-standing concerns regarding the quality of generic drugs. According to the results, 100 percent of the samples passed established quality benchmarks, showing no meaningful difference between generic and branded medications. The average drug content was found to be 99.45 percent overall, with branded medicines at 101.35 percent and generics at 99.10 percent, all within acceptable limits.

The price differences, however, were stark. Branded drugs averaged Rs 11.17 per tablet, while Jan Aushadhi generics were priced at just Rs 2.40 on average, making generics approximately 49 percent cheaper. For instance, the branded drug Pantoprazole costs Rs 16.82 per pill, whereas its generic version is only Rs 1.21. This striking price disparity, with generics being up to 14 times cheaper, has significant implications for consumers in India, where many struggle to afford necessary medications.

The study analyzed a range of medicines, including antibiotics, heart medications, diabetes drugs, and pain relievers. Samples were sourced from various outlets, including top branded products, branded generics, and Jan Aushadhi stores. The testing was conducted by Eureka Analytical Services Pvt Ltd, an accredited laboratory in Haryana, adhering to Indian Pharmacopoeia standards for parameters such as drug content, dissolution, uniformity, impurities, and physical appearance.

Dr. Cyriac Abby Philips, who led the initiative, shared the results on his social media account, stating, “Every single generic passed! Same quality as expensive brands, and up to 14x cheaper.” He highlighted the deep-rooted narrative that generic drugs are inferior, emphasizing that this study provides clear evidence to the contrary.

Despite the positive findings, the research uncovered some concerns. Products from Generic Aadhaar Pharmacy were found to be significantly more expensive than Jan Aushadhi equivalents in many instances, with prices ranging from 67 percent to 887 percent higher. This discrepancy calls for improved transparency and public quality data from policymakers, along with recommendations for pharmacists to substitute verified generics to enhance healthcare accessibility.

The implications of this research extend beyond mere statistics. As healthcare costs continue to escalate, the affordability of medications can profoundly affect the lives of many individuals and families. This study underscores the importance of reassessing perceptions about generic drugs and encourages policymakers to take action in ensuring that quality medications remain accessible to all.

Our Editorial team doesn’t just report the news—we live it. Backed by years of frontline experience, we hunt down the facts, verify them to the letter, and deliver the stories that shape our world. Fueled by integrity and a keen eye for nuance, we tackle politics, culture, and technology with incisive analysis. When the headlines change by the minute, you can count on us to cut through the noise and serve you clarity on a silver platter.

Continue Reading

Trending

Copyright © All rights reserved. This website offers general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information provided. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult relevant experts when necessary. We are not responsible for any loss or inconvenience resulting from the use of the information on this site.